BioArctic Stock

BioArctic Operating Cash Flow

The Operating Cash Flow of BioArctic (BIOA B.ST) as of Aug 10, 2026 is 1.43 B SEK. In the previous year, Operating Cash Flow was -316.33 M SEK — a change of -552.39% (higher).

Operating Cash Flow

1.43 BSEK

YoY

-552.39%

Last updated:

Operating Cash Flow of BioArctic is 2026 1.43 B SEK. Operating Cash Flow of BioArctic was 2025 -316.33 M SEK. It decreases by -552.39% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Operating Cash Flow of BioArctic is 1.43 B SEK in 2026.

Operating Cash Flow of BioArctic changed from -316.33 M SEK to 1.43 B SEK, representing a -552.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow BioArctic since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's BioArctic historically and in real time.

Access this data via the Eulerpool API

Cash Flow — BioArctic

All Key Metrics — BioArctic